Results 181 to 190 of about 59,128 (285)

p300‐Mediated H3K18 Lactylation Drives Radiation‐Induced Pulmonary Fibrosis via VIRMA‐Dependent m6A Modification of GATA3

open access: yesAdvanced Science, EarlyView.
Radiation triggers glycolytic reprogramming in alveolar epithelial type II cells, causing pathological lactate accumulation. This metabolic stress drives p300‐mediated H3K18 lactylation at the VIRMA promoter, activating transcription. Elevated VIRMA enriches m6A on GATA3 mRNA, which YTHDF1 stabilizes, ultimately driving epithelial–mesenchymal ...
Junxuan Yi   +8 more
wiley   +1 more source

A Synthetic Platform for Antibody Junctional Diversification Beyond Natural Constraints

open access: yesAdvanced Science, EarlyView.
ARESEC is a synthetic platform that reconstructs functional V(D)J recombination in HEK293T cells. By introducing RSS elements and co‐expressing RAG1/2 and TdT across all three antibody CDRs, it enables programmable junctional diversification and direct generation of high‐affinity variants targeting PD‐1/PD‐L1, overcoming the evolutionary constraints of
Wang Liu   +3 more
wiley   +1 more source

Autophagy Orchestrates Anti‐Tumor Immunity to Enhance Chemosensitivity via the FBXW2/C/EBPβ/TIMP‐2 Axis in Colorectal Cancer

open access: yesAdvanced Science, EarlyView.
Chemotherapy leverages tumor‐cell autophagy to reshape the colorectal cancer immune microenvironment. Autophagy degrades FBXW2 to promote C/EBPβ‐mediated TIMP‐2 transcription and MMP‐9 suppression, driving intra‐tumoral CD8+ T‐cell infiltration. Targeting MMP‐2/9 or restoring TIMP‐2 overcomes chemo‐resistance in autophagy‐deficient tumors. ABSTRACT The
Bing Cheng   +12 more
wiley   +1 more source

Targeting the PHB2–ACSL3 Lipid‐Remodeling Axis Overcomes Cisplatin Resistance by Restoring Ferroptosis in Gastric Cancer

open access: yesAdvanced Science, EarlyView.
ABSTRACT Platinum‐based chemotherapy resistance remains a major obstacle in gastric cancer (GC) treatment. Through integrated transcriptomic profiling of cisplatin‐resistant xenografts and pharmacogenomic interrogation of the NCI‐60 dataset, we identified Prohibitin‐2 (PHB2) as a previously unrecognized determinant of chemoresistance.
Liang Xu   +10 more
wiley   +1 more source

Repurposing FDA‐Approved Drugs to Inhibit Fungal PPTases for Broad‐Spectrum Synergy

open access: yesAdvanced Science, EarlyView.
Fungal secondary metabolites serve as crucial virulence effectors; however, the potential of their biosynthetic pathways as antifungal targets remains inadequately comprehended. Repurposed FDA‐approved drugs inhibit fungal PPTase (essential for secondary metabolism) in vivo.
Zili Song   +7 more
wiley   +1 more source

CHST1 Drives Immunotherapy Resistance in Triple‐Negative Breast Cancer by Orchestrating an Immunosuppressive Microenvironment via the NKRF–CCL20–Macrophage Axis

open access: yesAdvanced Science, EarlyView.
Proposed model of CHST1‐associated immune remodeling in triple‐negative breast cancer. In CHST1‐low tumors, greater nuclear accumulation of NKRF is associated with repression of an NF‐κB‐related CCL20 transcriptional program and an immune‐inflamed microenvironment.
Shu‐Hao Jiang   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy